What are the recommended colchicine and prednisone dosing regimens for an adult with an acute gout flare who has normal renal and hepatic function and no drug interactions?

Colchicine and Prednisone Dosing for Acute Gout

Colchicine Dosing for Acute Gout Flare

For an adult with normal renal and hepatic function presenting within 36 hours of symptom onset, administer colchicine 1.2 mg orally at the first sign of flare, followed by 0.6 mg one hour later (total 1.8 mg over one hour), then after a 12-hour pause resume 0.6 mg once or twice daily until the attack resolves. 1

Critical Timing Considerations

• Treatment must be initiated within 36 hours of symptom onset—colchicine effectiveness drops sharply beyond this window, and the American College of Rheumatology recommends against starting colchicine after this timeframe. 1
• Maximum benefit occurs when treatment begins within 12–24 hours of symptom onset; delaying beyond 24 hours markedly reduces efficacy. 1

Evidence Supporting Low-Dose Regimen

• This low-dose protocol (1.8 mg total) achieved approximately 42% treatment success versus 17% with placebo in the AGREE trial, with a number needed to treat of 5 for achieving ≥50% pain reduction at 24 hours. 1
• The low-dose regimen is equally effective as high-dose colchicine (4.8 mg over 6 hours) but produces significantly fewer gastrointestinal adverse effects. 1
• The older regimen of 0.5 mg every 2 hours until relief or toxicity is obsolete and causes severe diarrhea in most patients. 1

---

Prednisone Dosing for Acute Gout Flare

For an adult with normal renal and hepatic function, prescribe oral prednisone 0.5 mg/kg per day (approximately 30–35 mg daily for average-sized adults) for 5–10 days at full dose then stop abruptly, or alternatively give for 2–5 days at full dose followed by a 7–10 day taper. 2

Choosing Between Regimens

• For straightforward monoarticular involvement without significant comorbidities, use the simpler 5–10 day course without taper. 2
• For severe attacks, polyarticular involvement (≥4 joints), or patients at higher risk for rebound flares, use the tapered approach: 2–5 days at full dose followed by a 7–10 day taper. 2, 1

Evidence Quality

• The American College of Rheumatology provides Level A evidence (highest quality) supporting oral corticosteroids as equally effective as NSAIDs for acute gout treatment, with fewer adverse effects. 2
• The European League Against Rheumatism recommends prednisolone 30–35 mg daily for 3–5 days as first-line therapy, demonstrating 27% adverse events versus 63% with indomethacin. 2

Alternative Corticosteroid Routes

• For involvement of 1–2 large, accessible joints, intra-articular corticosteroid injection (dose varies by joint size) is an excellent alternative that provides targeted therapy with minimal systemic effects. 2
• Intramuscular triamcinolone acetonide 60 mg is the specifically recommended IM dose for acute gout when oral access is limited or the patient is NPO. 2

---

Selecting Between Colchicine and Prednisone

When Prednisone is Preferred

• Severe renal impairment (eGFR <30 mL/min): Prednisone requires no dose adjustment and is the safest first-line option, whereas colchicine should be avoided entirely due to fatal toxicity risk. 2
• Cardiovascular disease or heart failure: Prednisone is safer than NSAIDs (which carry cardiovascular risks) and colchicine is also safe with potential cardioprotective effects. 2, 3
• Gastrointestinal risk factors (peptic ulcer disease, recent GI bleeding, anticoagulation): Prednisone offers fewer GI adverse effects than NSAIDs. 2
• Hepatic impairment or cirrhosis: Prednisone is preferred over NSAIDs, which are contraindicated. 2
• Presentation beyond 36 hours of symptom onset: Colchicine should not be initiated; prednisone remains effective. 1

When Colchicine is Preferred

• Early presentation (within 12–24 hours) in patients without contraindications: Colchicine achieves maximum efficacy when started early. 1
• Patients with diabetes mellitus: Short-term prednisone causes transient hyperglycemia requiring proactive insulin adjustment, whereas colchicine does not affect glucose control. 2
• Patients with osteoporosis: Short courses (5–10 days) of prednisone pose minimal bone density risk, but colchicine avoids this concern entirely. 2
• Patients requiring long-term prophylaxis during urate-lowering therapy initiation: Low-dose colchicine 0.6 mg once or twice daily is first-line for 3–6 months, whereas prednisone >10 mg/day for prophylaxis is inappropriate. 2, 1

---

Combination Therapy for Severe Attacks

For severe acute gout with polyarticular involvement (≥4 joints) or multiple large joints, initiate combination therapy with colchicine plus prednisone, or intra-articular steroids plus any oral agent. 2, 1

• Combination therapy provides synergistic anti-inflammatory effects targeting different pathways. 1
• Acceptable combinations include: colchicine + oral corticosteroids, or intra-articular corticosteroids + colchicine. 2
• Avoid combining NSAIDs with systemic corticosteroids due to synergistic gastrointestinal toxicity. 2, 1

---

Absolute Contraindications

Colchicine Contraindications

• Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors (clarithromycin, erythromycin, cyclosporine, ketoconazole, ritonavir, verapamil), especially with any degree of renal or hepatic impairment—this combination can cause fatal toxicity, multiorgan failure, and death. 1
• Severe renal impairment (eGFR <30 mL/min): Colchicine should be avoided entirely; alternative therapy is strongly recommended. 1
• Combined hepatic-renal insufficiency: Absolute contraindication even without drug interactions. 4

Prednisone Contraindications

• Systemic fungal infections: Absolute contraindication for corticosteroid therapy. 2
• Active or uncontrolled infection: Corticosteroids cause immune suppression and can worsen infections. 2

---

Monitoring Response and Inadequate Response

• Define inadequate response as either <20% improvement in pain within 24 hours OR <50% improvement at ≥24 hours after initiating therapy. 2
• If inadequate response occurs, consider alternative diagnoses, switch to another monotherapy, or add a second agent. 2

---

Critical Pitfalls to Avoid

• Do not interrupt ongoing urate-lowering therapy (allopurinol, febuxostat) during an acute gout attack—continuation maintains serum urate control and does not worsen the flare. 1
• Do not delay treatment beyond 24 hours of symptom onset—efficacy of all acute therapies declines markedly with delayed initiation. 2, 1
• Do not use high-dose prednisone (>10 mg/day) for prophylaxis during urate-lowering therapy initiation—this increases long-term corticosteroid complications. 2
• Do not attempt colchicine dose reduction as a "compromise" in patients with renal impairment taking CYP3A4/P-gp inhibitors—even a single 0.6 mg dose carries unacceptable toxicity risk. 1